The NICE recommendations tell GPs to consider testing in anyone with one symptom or one risk factor, and to treat early to prevent neurological damage that can become permanent
The trial enrolled adults with overweight or obesity and randomised them to receive CagriSema, cagrilintide alone, semaglutide alone, or placebo over 32 weeks
GHK-Cu promotes follicle enlargement via Wnt signalling, while minoxidil increases blood flow via potassium channel opening
Designed with GlutaONE liposomal technology for enhanced effectiveness
Reconstitute with bacteriostatic water (typically 2 mL for a 50 mg vial), injecting the water slowly down the vial wall to avoid foaming
In the REDEFINE-1 Phase 3 trial, people on CagriSema lost an average of 22.7% of their body weight over 68 weeks when accounting only for those who stayed on treatment